Surgical approach matters for long-term lung cancer outcomes

Based on: Mercier O. Surgical approach matters for long-term lung cancer outcomes. The Lancet. 2026;407(10534):1125-1126.

Somewhere around the 1990s, a few brave thoracic surgeons looked at the enormous chest incision they'd been using for decades to remove lung tumors and thought: "What if we just... didn't?" That question kicked off a slow-burning revolution in lung cancer surgery, and a new meta-analysis just handed down the verdict: the size of the cut really does matter for how long patients live.

Small Holes, Big Deal

For most of lung surgery's history, getting to a tumor meant a thoracotomy - basically cracking open the ribcage with a wound that could stretch eight inches across. It works. It's also about as gentle on the body as a bar fight. Then came video-assisted thoracoscopic surgery, or VATS, where surgeons slip a tiny camera and instruments through a few keyhole incisions, remove the cancerous lobe, and leave your ribs largely unbothered.

Surgeons figured out pretty quickly that VATS patients went home sooner, popped fewer painkillers, and had fewer complications. But the trillion-dollar question lingered: does the approach actually help patients survive longer, or does it just make the recovery Instagram-worthy?

The Numbers That Settled The Argument

A landmark individual patient data meta-analysis, led by Jacie Jiaqi Law at the Royal Brompton Hospital and published in The Lancet, pooled results from three randomized controlled trials spanning Denmark, China, and the United Kingdom (Law et al., 2026). These weren't observational studies where surgeon preference muddies the water - patients were randomly assigned to VATS or open surgery. Coin flip, then scalpel.

The tally: 1,185 early-stage lung cancer patients, 586 in the VATS group, 599 going open. The result? VATS slashed the overall risk of death by 21% (hazard ratio 0.79, 95% CI 0.65-0.96). Disease-free survival was statistically similar between groups, meaning VATS wasn't "cheating" by somehow missing cancer - it removed the tumor just as thoroughly. Patients simply lived longer afterward.

In an accompanying commentary, thoracic surgeon Olaf Mercier of Marie Lannelongue Hospital in Paris underscored the weight of this finding: when something as straightforward as the way you enter the chest translates to a one-in-five reduction in mortality, that's not a footnote - that's a mandate (Mercier, 2026).

So Why Would A Smaller Incision Keep You Alive Longer?

Here's where it gets biologically interesting. Open thoracotomy doesn't just hurt more - it triggers a much larger inflammatory cascade. Your body floods the zone with cytokines like IL-6 and IL-8, and in the chaos, your immune system takes a hit right when you need it most. Natural killer cells, the immune system's elite tumor-hunting squad, drop significantly more after open surgery than after VATS (Craig et al., 2001). T-cell counts crater. Cellular cytotoxicity - your body's ability to kill any cancer cells still floating around after surgery - is nearly twice as high on postoperative day two in VATS patients compared to thoracotomy patients (Jones et al., 2014).

Think of it this way: open surgery is like fighting a house fire while someone simultaneously slashes the tires on every fire truck in the district. VATS puts out the fire and leaves the trucks running.

What This Means Going Forward

Lung cancer remains the leading cause of cancer death worldwide, with roughly 225,000 new cases diagnosed annually in the US alone. About 80-85% are non-small cell lung cancer, and thanks to expanded CT screening, more patients are being caught at early stages where surgery can cure them. The five-year survival for localized lung cancer is now around 64% - a number that, based on this evidence, could climb if every eligible patient got VATS instead of open surgery.

The three trials pooled here - the PLEACE trial from Denmark, Long et al. from China, and the VIOLET trial from the UK - spanned different healthcare systems, surgical traditions, and patient populations. The fact that the survival benefit held across all of them makes this harder to wave away as a statistical fluke.

Not every patient or tumor is suitable for VATS, and experienced hands behind the scope matter enormously. But for early-stage, resectable NSCLC, the evidence now says something surgeons suspected for years: how you get in determines how long you stick around.

References

1. Law JJ, Harris RA, et al. Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials. The Lancet. 2026;407(10534). DOI: 10.1016/S0140-6736(26)00031-0

2. Mercier O. Surgical approach matters for long-term lung cancer outcomes. The Lancet. 2026;407(10534):1125-1126. DOI: 10.1016/S0140-6736(26)00505-2. PMID: 41864735

3. Craig SR, Leaver HA, Yap PL, et al. Acute phase responses following minimal access and conventional thoracic surgery. European Journal of Cardio-Thoracic Surgery. 2001;20(2):455-463. DOI: 10.1016/S1010-7940(01)00839-1

4. Jones RO, Anderson NH, Breen DP, et al. Innate immune responses after resection for lung cancer via video-assisted thoracoscopic surgery and thoracotomy. European Journal of Surgical Oncology. 2014;40(10):1283-1289. DOI: 10.1016/j.ejso.2013.12.002. PMID: 24755536

5. Bendixen M, Jørgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. The Lancet Oncology. 2016;17(6):836-844. DOI: 10.1016/S1470-2045(16)00173-X. PMID: 27160473

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.